TQB2922 subcutaneous treatment for advanced cancers

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

TQB2922 is being given by subcutaneous injection to adults with advanced non-squamous non-small cell lung cancer in a Phase I dose-finding and pharmacokinetics study. The main goals are to determine safety, tolerability, and how the drug is processed by the body, and to identify appropriate dosing. Eligible participants must have ECOG 0–1, expected survival over 12 weeks, a measurable progressive lesion within a prior radiotherapy area per RECIST 1.1, and have received standard treatment or lack effective options. The trial is enrolling at three cancer centers in China and requires regular clinic visits for dosing and follow-up.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Subjects voluntarily joined this study, signed the informed consent form, and had good compliance；
* 18-75 yeas old；
* Eastern Cooperative Oncology Group Performance Status (ECOG) score: 0-1;
* Expected survival of more than 12 weeks；
* Histologically or cytologically diagnosed with advanced non-squamous non-small cell lung cancer
* Subjects in cohorts 1a/1b/2a/2b need to have received standard treatment or lack effective treatment.
* There must be at least one measurable lesion within the radiotherapy area that can be clearly classified as progressive according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST1.1) criteria.
* Major organs are functioning well；
* Female and male subjects of childbearing potential should agree to practice contraception for the duration of the study and for 6 months after the end of the study.

Exclusion Criteria:

* Current concomitant presence of other malignancies within 5 years prior to the first dose；
* At the time of initiating the study of treatment, the adverse reactions caused by previous anti-tumor treatments failed to recover to a CTCAE 5.0 score of grade 1 or below.
* Patients who had received major surgical treatment within 4 weeks prior to the first study, had obvious traumatic injuries, or were expected to undergo major surgery during the study treatment period, or had long-term unhealed wounds or fractures.
* Hyperactive or venous thrombosis events occurred within 6 months before the first administration;
* Major cardiovascular diseases;
* Active hepatitis
* Those with a history of psychotropic drug abuse who are unable to quit or have mental disorders.
* There was an active infection (≥ Common Terminology Criteria for Adverse Events version 5.0 (CTCAE5.0) score of grade 2) within 2 weeks before the first administration;
* Patients with renal failure requiring hemodialysis or peritoneal dialysis;
* Patients who have a history of immune deficiency.
* Patients who have epilepsy and need treatment;
* Evidence of a previous history of interstitial lung disease, drug-induced interstitial lung disease, radiation pneumonitis requiring steroid treatment, or any clinically active interstitial lung disease.
* Those who have participated in and used other anti-tumor clinical trial drugs within 4 weeks before the first treatment.
* Pregnant or lactating women.
* There is any serious or uncontrolled systemic disease.

Where it's running

• Sun Yat-sen University Cancer Center
  Guangzhou, Guangdong, China Recruiting
• Henan Cancer Hospital
  Zhengzhou, Henan, China Recruiting
• Nanjing Drum Tower Hospital
  Nanjing, Jiangsu, China Recruiting
• The First Affiliated Hospital of Nanchang University
  Nanchang, Jiangxi, China Recruiting
• Affiliated Zhongshan Hospital of Dalian University
  Dalian, Liaoning, China Recruiting
• Shandong Cancer Hospital
  Jinan, Shandong, China Recruiting

Study contacts

• Study coordinator: Li Zhang, Doctor
• Email: zhangli@sysucc.org.cn
• Phone: 020-87343458

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Testing TQB3107 tablets in patients with advanced cancers

  This study is testing TQB3107 tablets to see if they are safe and effective for people with advanced cancers.

  Recruiting at 11 sites Phase 1 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Guangzhou, Guangdong and 11 other locations · NCT06413953

• Personalized cancer treatment based on genomic analysis

  This study is testing whether personalized cancer treatments based on each patient's unique genetic makeup can improve outcomes for people with advanced cancers.

  Recruiting British Columbia Cancer Agency · Vancouver, British Columbia · NCT02155621

• TQF3250 Capsules in overweight and obese adults with limited weight loss from lifestyle changes

  This phase 1b study tests whether TQF3250 capsules are safe and tolerable, and whether they show preliminary signs of benefit, in adults with overweight or obesity who have not achieved enough weight loss with simple lifestyle changes.

  Recruiting at 6 sites Phase 1 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Beijing, Beijing Municipality and 9 other locations · NCT07798284

• TQF3250 capsules for adults with type 2 diabetes and overweight/obesity

  A small, early-phase study will test the safety and how the body handles different doses of TQF3250 pills in adults with type 2 diabetes who are overweight or obese.

  Recruiting Phase 1 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Fuzhou, Fujian and 11 other locations · NCT07747857

• GPC3-targeted ADC for advanced solid tumors

  This early-phase trial tests a Glypican-3 targeted antibody-drug conjugate (TQB6426) in adults with advanced cancers to see if it is safe and tolerable and to explore potential anti-tumor activity.

  Recruiting Phase 1 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Hefei, Anhui and 7 other locations · NCT07730190

• TQH3906 capsules vs warmer options in adults with moderate to severe plaque psoriasis

  This Phase 3 trial tests whether once-daily TQH3906 capsules can help adults with moderate to severe plaque psoriasis better than a placebo or the active drug deucravacitinib.

  Recruiting at 13 sites Phase 3 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Beijing, Beijing Municipality and 44 other locations · NCT07724366

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.